Log In
Print
BCIQ
Print
Print this Print this
 

EZN-2279

  Manage Alerts
Collapse Summary General Information
Company Sigma-Tau Group
DescriptionPegylated recombinant adenosine deaminase
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard Indication Metabolic (unspecified)
Indication DetailsTreat adenosine deaminase deficiency
Regulatory Designation

Partner

Teijin Pharma Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today